Policy & Regulation
Health Canada approves AbbVie psoriasis treatment for children
20 October 2026 - American pharmaceutical company AbbVie (NYSE: ABBV) on Tuesday said Health Canada has approved SKYRIZI (risankizumab) for patients aged six to under 18 with moderate to severe plaque...
WuXi AppTec recognised in Frost & Sullivan's Global Company of the Year awards for Tenth Consecutive Year
20 October 2026 - WuXi AppTec Co., Ltd. (SSE: 603259; HKEX: 2359), a China-based global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organisation), said on Monday it has rec...
Oracle partners AstraZeneca for AI-enabled healthcare innovation
20 October 2026 - US-based tech firm Oracle Corporation (NYSE: ORCL) announced on Tuesday an agreement with UK-based pharmaceutical company AstraZeneca (LON: AZN) to explore how AI and real-world data...
Eli Lilly and Company reports positive one-year results for Omvoh in paediatric ulcerative colitis
19 October 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) reported on Mondy that it has recorded positive one-year Phase 3 results for Omvoh (mirikizumab-mrkz) in children and adolescents w...
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
19 October 2026 - Pharmaceutical research and development company AbbVie (NYSE: ABBV) reported on Monday that its investigational dual-targeting therapy ABBV-466 achieved higher endoscopic remission r...
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
19 October 2026 - Japan-based biopharmaceutical company Takeda (TSE: 4502) (NYSE: TAK) announced on Monday that positive Phase IV VERDICT trial results show that treating adults with moderate to sever...